Henagliflozin in Patients With Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT05252624

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05252624
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05252624. Randomized; triple masking; primary purpose prevention. Start 2022-09-01 (anticipated); primary completion 2023-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Henagliflozin in Patients With Atrial Fibrillation
Acronym
HENA-AF
Intervention (Drug)
placebo
Intervention (Drug)
Henagliflozin 5Mg Tab
Lead sponsor
Beijing Anzhen Hospital (class: other)

Record details

Record id
cardio:ct-nct05252624
Content hash
4d837aac0a6dd3a63ebfb8f01278b57e1df5a739a9b240ba8af30cb6fe950ae3